Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease

Dow Jones

Feb 04, 2025

By Colin Kellaher

Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.

Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder.

The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter.

Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses.

Shares of Supernus were recently up 5.5% to $39.42.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

February 04, 2025 10:10 ET (15:10 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2508463961"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2508463961\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2508463961?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-04 23:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2508463961","market":"hk","top_or_hot":-1,"title":"Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease. \n</p>\n<p>\n  Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder. \n</p>\n<p>\n  The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter. \n</p>\n<p>\n  Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses. \n</p>\n<p>\n  Shares of Supernus were recently up 5.5% to $39.42. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2025 10:10 ET (15:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Supernus Gets FDA Approval of Onapgo Device for Parkinson's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSupernus Gets FDA Approval of Onapgo Device for Parkinson's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-02-04 23:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease. \n</p>\n<p>\n  Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder. \n</p>\n<p>\n  The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter. \n</p>\n<p>\n  Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses. \n</p>\n<p>\n  Shares of Supernus were recently up 5.5% to $39.42. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  February 04, 2025 10:10 ET (15:10 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2508463961","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2508463961","pubTimestamp":1738681800,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Supernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease.Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder.The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter.Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses.Shares of Supernus were recently up 5.5% to $39.42.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","SUPN":"Supernus Pharmaceuticals"},"translate_title":"Supernus治疗帕金森病的Onapgo设备获得FDA批准","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SUPN":0.9},"content_text":"By Colin Kellaher \n\n\n \n\n\nSupernus Pharmaceuticals has won Food and Drug Administration approval for its Onapgo device to treat patients with Parkinson's disease. \n\n\n  Supernus on Tuesday said the FDA green light makes Onapgo the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced forms of the neurodegenerative disorder. \n\n\n  The Rockville, Md., biopharmaceutical company said it plans to make Onapgo available in the second quarter. \n\n\n  Supernus said Onapgo is a wearable infusion device that provides continuous treatment during the waking day for more consistent control of off periods, which can occur in people with Parkinson's disease when there is a return of symptoms in between medication doses. \n\n\n  Shares of Supernus were recently up 5.5% to $39.42. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 04, 2025 10:10 ET (15:10 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}